Long Non-coding RNA ZFPM2-AS1: A Novel Biomarker in the Pathogenesis of Human Cancers

Mol Biotechnol. 2022 Jul;64(7):725-742. doi: 10.1007/s12033-021-00443-3. Epub 2022 Jan 31.

Abstract

Due to their biological activities in regulating dosage compensation, epigenetics, and cell differentiation, long non-coding RNAs (lncRNA) have been recognized as important regulators of the beginning and development of human malignancies. LncRNA dysregulation has a significant impact on a range of cellular functions, including proliferation, migration, invasion, and anti-apoptosis activity. Recently, aberrant expression of the long non-coding RNA zinc finger protein multitype 2 antisense RNA 1 (ZFPM2-AS1) was observed in a range of solid tumors and correlated significantly with tumor size, histological differentiation, lymph node metastasis, malignant tumor (TNM) stage, short survival, and prognosis. Additional mechanical analysis indicated that ZFPM2-AS1 was involved in several cellular activities, including proliferation, migration, invasion, cell cycle progression, and apoptosis, through microRNAs (miRNAs), signaling pathways, and other biological components or proteins. This review summarizes the current status of research on ZFPM2-AS1 in various human malignancies and discusses its mechanism of action and clinical significance in tumor development and progression.

Keywords: Biomarker; Cancer; Pathogenesis; ZFPM2-AS1; lncRNAs.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Cell Line, Tumor
  • Cell Movement
  • Cell Proliferation / genetics
  • DNA-Binding Proteins / genetics
  • Gene Expression Regulation, Neoplastic
  • Humans
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Neoplasms* / genetics
  • RNA, Antisense
  • RNA, Long Noncoding* / genetics
  • RNA, Long Noncoding* / metabolism
  • Transcription Factors / genetics

Substances

  • Biomarkers
  • DNA-Binding Proteins
  • MicroRNAs
  • RNA, Antisense
  • RNA, Long Noncoding
  • Transcription Factors
  • ZFPM2 protein, human